cilostazol has been researched along with Coronary Artery Disease in 45 studies
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-one patients with coronary artery disease (CAD) were assigned to one of two groups: the Cilostazol(+) group (with cilostazol) and Cilostazol(-) group (without cilostazol)." | 9.22 | The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease. ( Ebato, M; Iso, Y; Maeda, A; Mori, H; Sasai, M; Sato, T; Suzuki, H; Tashiro, K; Wakabayashi, K, 2016) |
| "This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy." | 9.17 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 6.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| "Cilostazol has been reported to control restenosis after balloon angioplasty (BA)." | 6.71 | Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS. ( Awata, N; Kobayashi, T; Nasu, K; Takeda, Y; Tsuchikane, E, 2004) |
| "Previously, in the ESCAPE study, a randomized controlled trial, we found that 12 months of cilostazol administration significantly decreased coronary artery stenosis and the noncalcified plaque component compared with aspirin." | 5.51 | Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study. ( Chun, EJ; Lim, S; Sohn, M, 2022) |
| "Hypercholesterolemic patients with coronary artery disease were randomized to three groups and received study drugs for 3 years: the control with statin alone; the probucol group with statin and probucol; and the combo group with statin, probucol, and cilostazol." | 5.41 | Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study. ( Ge, J; Kang, HJ; Kim, CH; Kim, MH; Kim, SH; Oh, BH; Park, JE; Sung, J, 2021) |
| "Cilostazol has been reported to control neointimal proliferation after stenting." | 5.31 | Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT). ( Awata, N; Kobayashi, T; Otsuji, S; Sakurai, M; Takeda, Y; Tsuchikane, E, 2002) |
| "Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications." | 5.22 | Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. ( Manolis, AA; Manolis, AS; Manolis, TA; Melita, H; Mikhailidis, DP, 2022) |
| "Fifty-one patients with coronary artery disease (CAD) were assigned to one of two groups: the Cilostazol(+) group (with cilostazol) and Cilostazol(-) group (without cilostazol)." | 5.22 | The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease. ( Ebato, M; Iso, Y; Maeda, A; Mori, H; Sasai, M; Sato, T; Suzuki, H; Tashiro, K; Wakabayashi, K, 2016) |
| "This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy." | 5.17 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "Cilostazol is the only first-line medication for treating intermittent claudication, and the controlled-release (CR) formulation is associated with a lower prevalence of adverse events (AEs)." | 4.31 | Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease. ( Kim, JH; Lee, HJ; Shin, WY, 2023) |
| " Sex-specific odds ratios of age, diabetes mellitus (DM), hypertension (HTN), coronary artery disease (CAD), cerebral vascular accident (CVA), or using cilostazol for LEA or PRP were explored." | 3.77 | Determinants of lower extremity amputation or revascularization procedure in patients with peripheral artery diseases: a population-based investigation. ( Chen, JJ; Lee, CH; Liau, CS; Lin, LY, 2011) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 2.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| "Cilostazol has been reported to control restenosis after balloon angioplasty (BA)." | 2.71 | Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS. ( Awata, N; Kobayashi, T; Nasu, K; Takeda, Y; Tsuchikane, E, 2004) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| " There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target-lesion revascularization in the triple-therapy group (OR: 0." | 2.48 | The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. ( He, J; He, Y; Liu, G; Ma, C; Tang, P; Wang, P; Yang, J; Zhou, R; Zhou, S, 2012) |
| "Colchicine is a microtubule-destabilizing agent that may enhance the synthesis of cAMP." | 1.72 | Cardiovascular Protection Associated With Cilostazol, Colchicine, and Target of Rapamycin Inhibitors. ( Adeva-Andany, MM; Carneiro-Freire, N; Castro-Quintela, E; Fernández-Fernández, C; González-Lucán, M; Vila-Altesor, M, 2022) |
| "Cilostazol has been reported to control neointimal proliferation after stenting." | 1.31 | Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT). ( Awata, N; Kobayashi, T; Otsuji, S; Sakurai, M; Takeda, Y; Tsuchikane, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (26.67) | 29.6817 |
| 2010's | 27 (60.00) | 24.3611 |
| 2020's | 6 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Manolis, AA | 1 |
| Manolis, TA | 1 |
| Melita, H | 1 |
| Mikhailidis, DP | 1 |
| Manolis, AS | 1 |
| Adeva-Andany, MM | 1 |
| Fernández-Fernández, C | 1 |
| Carneiro-Freire, N | 1 |
| Castro-Quintela, E | 1 |
| Vila-Altesor, M | 1 |
| González-Lucán, M | 1 |
| Sohn, M | 1 |
| Chun, EJ | 1 |
| Lim, S | 1 |
| Shin, WY | 3 |
| Lee, HJ | 1 |
| Kim, JH | 4 |
| Kang, HJ | 2 |
| Kim, MH | 2 |
| Sung, J | 1 |
| Kim, SH | 1 |
| Kim, CH | 1 |
| Park, JE | 1 |
| Ge, J | 2 |
| Oh, BH | 1 |
| Dai, C | 1 |
| Chen, Z | 1 |
| Fu, J | 1 |
| Qian, J | 1 |
| Lee, CH | 2 |
| Lee, JY | 4 |
| Park, GM | 3 |
| Lee, SW | 7 |
| Kim, HS | 6 |
| Choi, YJ | 2 |
| Nam, CW | 2 |
| Cho, JH | 1 |
| Seo, JB | 1 |
| Choi, SW | 4 |
| Lee, JH | 5 |
| Min, PK | 1 |
| Her, SH | 1 |
| Lee, PH | 1 |
| Ahn, JM | 3 |
| Park, DW | 6 |
| Kang, SJ | 5 |
| Kim, YH | 7 |
| Lee, CW | 7 |
| Park, SW | 7 |
| Park, SJ | 7 |
| Zhuo, X | 1 |
| Zhuo, B | 1 |
| Ouyang, S | 1 |
| Niu, P | 1 |
| Xiao, M | 1 |
| Chen, YC | 1 |
| Lin, FY | 1 |
| Lin, YW | 1 |
| Cheng, SM | 1 |
| Chang, CC | 1 |
| Lin, RH | 1 |
| Chuang, CL | 1 |
| Sheu, JS | 1 |
| Chen, SM | 1 |
| Tsai, CS | 1 |
| Panchal, HB | 1 |
| Shah, T | 1 |
| Patel, P | 1 |
| Albalbissi, K | 1 |
| Molnar, J | 1 |
| Coffey, B | 1 |
| Khosla, S | 1 |
| Ramu, V | 1 |
| Han, S | 2 |
| Cho, YR | 2 |
| Lee, WS | 2 |
| Jang, JY | 2 |
| Kwon, CH | 2 |
| Kim, WJ | 3 |
| Kim, JJ | 2 |
| Park, KW | 1 |
| Kang, SH | 1 |
| Park, JJ | 1 |
| Yang, HM | 1 |
| Koo, BK | 1 |
| Park, BE | 1 |
| Cha, KS | 1 |
| Rhew, JY | 1 |
| Jeon, HK | 1 |
| Shin, ES | 2 |
| Oh, JH | 2 |
| Jeong, MH | 2 |
| Kim, S | 1 |
| Hwang, KK | 1 |
| Yoon, JH | 1 |
| Lee, SY | 1 |
| Park, TH | 1 |
| Moon, KW | 1 |
| Kwon, HM | 2 |
| Chae, IH | 2 |
| Lavie, CJ | 1 |
| DiNicolantonio, JJ | 1 |
| Park, YK | 1 |
| Ha, SJ | 1 |
| Kim, SJ | 1 |
| Hwang, SJ | 1 |
| Woo, JS | 2 |
| Kim, W | 2 |
| Kim, WS | 2 |
| Kim, KS | 1 |
| Kim, MK | 2 |
| Youn, YJ | 1 |
| Lee, JW | 1 |
| Ahn, SG | 1 |
| Lee, SH | 4 |
| Choi, H | 1 |
| Yu, CW | 1 |
| Hong, YJ | 1 |
| Hong, MK | 3 |
| Jang, Y | 3 |
| Yoon, J | 1 |
| Song, PS | 1 |
| Song, YB | 1 |
| Yang, JH | 1 |
| Hahn, JY | 1 |
| Choi, SH | 3 |
| Choi, JH | 1 |
| Seung, KB | 3 |
| Gwon, HC | 1 |
| Ko, YG | 3 |
| Chol Kang, W | 1 |
| Kwon Lee, B | 1 |
| Wook Kim, S | 1 |
| Shim, WH | 2 |
| Kwon, BJ | 1 |
| Kim, DB | 1 |
| Park, HJ | 2 |
| Jang, SW | 1 |
| Ihm, SH | 1 |
| Kim, HY | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Mori, H | 1 |
| Maeda, A | 1 |
| Wakabayashi, K | 1 |
| Sato, T | 1 |
| Sasai, M | 1 |
| Tashiro, K | 1 |
| Iso, Y | 1 |
| Ebato, M | 1 |
| Suzuki, H | 1 |
| de Donato, G | 1 |
| Setacci, F | 1 |
| Mele, M | 1 |
| Giannace, G | 1 |
| Galzerano, G | 1 |
| Setacci, C | 1 |
| Zuliani Mauro, MF | 1 |
| Mangione, JA | 1 |
| Costa, JR | 1 |
| Costa, R | 1 |
| Piva E Mattos, LA | 1 |
| Staico, R | 1 |
| Feres, F | 1 |
| Siqueira, D | 1 |
| Sousa, A | 1 |
| Abizaid, A | 1 |
| Angiolillo, DJ | 2 |
| Capranzano, P | 2 |
| Goto, S | 1 |
| Aslam, M | 1 |
| Desai, B | 2 |
| Charlton, RK | 1 |
| Suzuki, Y | 1 |
| Box, LC | 1 |
| Shoemaker, SB | 1 |
| Zenni, MM | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Grove, EL | 1 |
| Kristensen, SD | 1 |
| Lee, JM | 1 |
| Park, S | 1 |
| Shin, DJ | 1 |
| Choi, D | 1 |
| Shim, CY | 1 |
| Kim, JS | 1 |
| Chang, CW | 1 |
| Lee, JE | 1 |
| Chen, JJ | 1 |
| Lin, LY | 1 |
| Liau, CS | 1 |
| Woo, KS | 1 |
| Kim, BR | 1 |
| Kim, JE | 1 |
| Goh, RY | 1 |
| Yu, LH | 1 |
| Han, JY | 1 |
| Kim, BK | 1 |
| Lee, BK | 2 |
| Kang, WC | 2 |
| Kim, SW | 1 |
| Lee, M | 1 |
| Honda, Y | 1 |
| Fitzerald, PJ | 1 |
| Kim, PJ | 1 |
| Yun, SC | 3 |
| Seong, IW | 3 |
| Lee, NH | 3 |
| Cho, YH | 3 |
| Lee, SJ | 1 |
| Hyon, MS | 1 |
| Bang, DW | 1 |
| Lee, K | 1 |
| Park, HK | 1 |
| Park, CB | 1 |
| Lee, SG | 1 |
| Park, KH | 1 |
| Park, WJ | 1 |
| Lee, SR | 1 |
| Jung, KH | 1 |
| Lew, JH | 1 |
| Lee, TW | 1 |
| Lim, CK | 1 |
| Ferreiro, JL | 1 |
| Ueno, M | 1 |
| Capodanno, D | 1 |
| Dharmashankar, K | 1 |
| Darlington, A | 1 |
| Tello-Montoliu, A | 1 |
| Rollini, F | 1 |
| Wang, P | 1 |
| Zhou, S | 1 |
| Zhou, R | 1 |
| Liu, G | 1 |
| Tang, P | 1 |
| He, J | 1 |
| Ma, C | 1 |
| He, Y | 1 |
| Yang, J | 1 |
| Bertelli, L | 1 |
| Amato, A | 1 |
| Sangiorgi, GM | 1 |
| Belardi, JA | 1 |
| Albertal, M | 1 |
| Tsuchikane, E | 2 |
| Kobayashi, T | 3 |
| Takeda, Y | 2 |
| Otsuji, S | 1 |
| Sakurai, M | 1 |
| Awata, N | 2 |
| Nasu, K | 1 |
| Inoue, T | 1 |
| Uchida, T | 1 |
| Sakuma, M | 1 |
| Imoto, Y | 1 |
| Ozeki, Y | 1 |
| Ozaki, Y | 1 |
| Hikichi, Y | 1 |
| Node, K | 1 |
| Conti, CR | 1 |
| Ujiie, Y | 1 |
| Hirosaka, A | 1 |
| Mitsugi, M | 1 |
| Ohwada, T | 1 |
| Igarashi, M | 1 |
| Kijima, M | 1 |
| Komatsu, N | 1 |
| Hisa, S | 1 |
| Abe, Y | 1 |
| Tsuda, T | 1 |
| Yaoita, H | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 1 |
| Douglas, JS | 1 |
| Ko, JK | 2 |
| Park, JH | 2 |
| Chun, KJ | 2 |
| Ahn, Y | 1 |
| Jeong, JW | 1 |
| Kim, KH | 1 |
| Ahn, TH | 1 |
| Park, CG | 1 |
| Hur, SH | 1 |
| Bae, JH | 1 |
| Kim, KY | 1 |
| Oh, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02101437] | 175 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation[NCT01192724] | Phase 4 | 630 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [NCT01031667] | Phase 4 | 118 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions[NCT00589927] | Phase 4 | 486 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"miRNA-365-3p measure by Roche miRNA kits; PRP(platelet riched plasma) isolated miRNA by isolation Kit, then havest in cDNA synthesis Kit; then perform RT PCR.~." (NCT02101437)
Timeframe: 7 days
| Intervention | fold of change (Mean) |
|---|---|
| Control | -8.14 |
| Clopidogrel | -3.46 |
| Ticagrelor | -7.54 |
| Clopidogrel+Cilostazol | -3.97 |
8 reviews available for cilostazol and Coronary Artery Disease
| Article | Year |
|---|---|
Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
Topics: Animals; Cilostazol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2022 |
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Humans; Observational Studies as Topic; P | 2018 |
Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinatio | 2013 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol.
Topics: Cardiovascular Agents; Cilostazol; Coronary Artery Disease; Coronary Restenosis; Endovascular Proced | 2017 |
Update on oral antiplatelet therapy: principles, problems and promises.
Topics: Adenosine; Administration, Oral; Cardiovascular Diseases; Cilostazol; Coronary Artery Disease; Coron | 2009 |
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Art | 2012 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease | 2007 |
26 trials available for cilostazol and Coronary Artery Disease
| Article | Year |
|---|---|
Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study.
Topics: Aspirin; Cilostazol; Coronary Artery Disease; Coronary Stenosis; Diabetes Mellitus, Type 2; Drug The | 2022 |
Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study.
Topics: Anticholesteremic Agents; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Cilost | 2021 |
Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREA
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method | 2018 |
Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Resistance; D | 2019 |
Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials).
Topics: Cilostazol; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relati | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Compl | 2013 |
Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.
Topics: Blood Platelets; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over | 2013 |
Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
Topics: Aged; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; D | 2014 |
Effects of combination therapy with cilostazol and probucol versus monotherapy with cilostazol on coronary plaque, lipid and biomarkers: SECURE study, a double-blind randomized controlled clinical trial.
Topics: Anticholesteremic Agents; Biomarkers; Bronchodilator Agents; Cilostazol; Coronary Artery Disease; Do | 2014 |
A randomized comparison study assessing the impact of cilostazol on the heart rate and arrhythmias by 24-hour ambulatory holter electrocardiographic monitoring after drug-eluting stent implantation for coronary artery disease.
Topics: Arrhythmias, Cardiac; Cilostazol; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting S | 2015 |
The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease.
Topics: Aged; Bronchodilator Agents; Cilostazol; Coronary Angiography; Coronary Artery Disease; Dilatation; | 2016 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona | 2017 |
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Ove | 2008 |
Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cilostazol; Clopidogrel; Confidence I | 2009 |
Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Biomarkers; Cilostazol; Coronary Angiograp | 2011 |
Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Cilostazol; Coronary | 2011 |
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Sten
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Double-Blind M | 2011 |
Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney di
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Chronic Disease; Cilostazol; Clopidogrel; Coronary Arte | 2011 |
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Over Studies | 2013 |
Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS.
Topics: Aged; Angioplasty, Balloon; Blood Vessel Prosthesis Implantation; Cilostazol; Combined Modality Ther | 2004 |
Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Cilostazol; Coronary Angiography; Coronary Artery Disease | 2004 |
Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; | 2006 |
Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vess | 2007 |
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
11 other studies available for cilostazol and Coronary Artery Disease
| Article | Year |
|---|---|
Cardiovascular Protection Associated With Cilostazol, Colchicine, and Target of Rapamycin Inhibitors.
Topics: Cilostazol; Colchicine; Coronary Artery Disease; Cyclic AMP; Diabetes Mellitus, Type 2; Humans; Musc | 2022 |
Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease.
Topics: Cilostazol; Coronary Artery Disease; Delayed-Action Preparations; Drug-Related Side Effects and Adve | 2023 |
Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary Drug-Eluting Stent Implantation.
Topics: Aspirin; China; Cilostazol; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2020 |
Cilostazol--a forgotten antiplatelet agent, but does it even matter?
Topics: Cilostazol; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Percuta | 2013 |
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2015 |
Determinants of lower extremity amputation or revascularization procedure in patients with peripheral artery diseases: a population-based investigation.
Topics: Aged; Amputation, Surgical; Cilostazol; Coronary Artery Disease; Female; Humans; Hypertension; Logis | 2011 |
Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Comb | 2010 |
Treatment of superficial and profunda femoral artery bifurcation lesions: still a procedure only for surgeons?
Topics: Aged; Atherosclerosis; Catheters; Chronic Disease; Cilostazol; Coronary Artery Bypass; Coronary Arte | 2012 |
Triple antiplatelet therapy with cilostazol: hitting the "sweet-spot".
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Te | 2013 |
Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT).
Topics: Aged; Atherectomy, Coronary; Blood Vessel Prosthesis Implantation; Cilostazol; Combined Modality The | 2002 |
Not just another restenosis trial.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Combined Modality Therapy; Coronary Artery Disease; Coro | 2004 |